BZYR · Burzynski Research Institute, Inc.

Burzynski Research Institute, Inc. faces imminent reporting delinquency as its primary funder, Dr. Stanislaw R. Burzynski—who serves as President, CFO, Chairman, and majority shareholder—has notified the Company of his inability to cover SEC Reporting Costs due to resource constraints. This directly threatens the timely filing of the Annual Report on Form 10-K for the fiscal year ended February 28, 2026, due on or about May 29, 2026, and ongoing periodic reports under Sections 13(a) and 15(d) of the Exchange Act. For investors, the stakes are severe: delinquency could prompt the SEC to issue a trading suspension order under Section 12(k), halting market activity in BZYR shares. More critically, persistent non-compliance may trigger administrative proceedings under Section 12(j) to suspend or revoke the Company's Exchange Act registration, effectively delisting it from public trading venues. Such outcomes would restrict broker-dealers from quoting the securities and could eliminate trading liquidity entirely, trapping shareholders. The filing underscores the Company's heavy historical reliance on Dr. Burzynski for operational funding, highlighting acute vulnerability to his personal financial capacity. Forward-looking statements note uncertainties around alternative financing, with actual SEC actions unpredictable based on facts and circumstances.